{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T14:37:17Z","timestamp":1794062237126,"version":"4.8.0"},"reference-count":26,"publisher":"Bioscientifica","issue":"7","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":224,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Teprotumumab, a monoclonal antibody that antagonizes the insulin-like growth factor 1 receptor, is the first medication within the United States to receive Food and Drug Administration (FDA) approval for thyroid eye disease (TED). The FDA recently issued a warning regarding otologic complications, such as hearing loss. We aimed to study the association between teprotumumab and sensorineural hearing loss in thyrotoxic patients with TED. A real-world retrospective cohort study was performed through the TriNetX Collaborative Network (globally de-identified database) over a 5-year period. Inclusion criteria were patients at least 18 years of age with a diagnosis of Graves\u2019 disease and TED, and were stratified into two cohorts: those treated with teprotumumab and those who were not. Propensity score-matching was performed for an even balance among cohorts (adjusting for age, sex, race, ethnicity, comorbidities, medications, smoking, and laboratory values), providing 532 patients per cohort. We identified a significantly higher risk difference of sensorineural hearing loss in patients treated with teprotumumab compared to those without exposure (risk difference 8.415%, 95% CI 4.954\u201311.876; 12.222 versus 3.808%), with a near three-fold increased relative risk for acquiring sensorineural hearing loss (risk ratio 3.21, 95% CI 1.936\u20135.323, P &amp;lt; 0.0001) over a 5-year period. Although the mechanism of teprotumumab-induced hearing loss remains unknown, and there is a lack of data to identify patients at risk (or those more likely to recover), our study confirms a higher risk for sensorineural hearing loss, which patients and providers alike must be aware of. Further studies providing prospective data are required to confirm such findings.<\/jats:p>","DOI":"10.1530\/ec-25-0293","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T22:25:04Z","timestamp":1752877504000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-10","source":"Crossref","is-referenced-by-count":6,"title":["Teprotumumab and sensorineural hearing loss: a propensity score-matched retrospective cohort study"],"prefix":"10.1530","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8709-2064","authenticated-orcid":true,"given":"Maxim John Levy","family":"Barnett","sequence":"first","affiliation":[{"name":"Jefferson-Einstein Hospital, Internal Medicine 1 , , ,","place":["Philadelphia, Pennsylvania, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Lam","sequence":"additional","affiliation":[{"name":"Jefferson-Einstein Hospital, Internal Medicine 1 , , ,","place":["Philadelphia, Pennsylvania, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikaela Nikkola","family":"Jara-Tantoco","sequence":"additional","affiliation":[{"name":"Jefferson-Einstein Hospital, Internal Medicine 1 , , ,","place":["Philadelphia, Pennsylvania, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Casipit","sequence":"additional","affiliation":[{"name":"Jefferson-Einstein Hospital, Internal Medicine 1 , , ,","place":["Philadelphia, Pennsylvania, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Eidbo","sequence":"additional","affiliation":[{"name":"Jefferson-Einstein Hospital, Internal Medicine 1 , , ,","place":["Philadelphia, Pennsylvania, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Anastasopoulou","sequence":"additional","affiliation":[{"name":"Jefferson-Einstein Hospital, Endocrinology, Diabetes & Metabolism 2 , , ,","place":["Philadelphia, Pennsylvania, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"2026070711000229800_bib1","doi-asserted-by":"crossref","first-page":"94","DOI":"10.4274\/tjo.80688","article-title":"Thyroid-associated ophthalmopathy","volume":"47","author":"\u015eahl\u0131","year":"2017","journal-title":"Turkish J Ophthalmol"},{"key":"2026070711000229800_bib2","first-page":"177","article-title":"Development and course of exophthalmos and ophthalmoplegia in Graves\u2019 disease with special reference to the effect of thyroidectomy","volume":"5","author":"Rundle","year":"1945","journal-title":"Clin Sci"},{"key":"2026070711000229800_bib3","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-22-0189","article-title":"Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association","volume":"11","author":"Burch","year":"2022","journal-title":"Eur Thyroid J"},{"key":"2026070711000229800_bib4","doi-asserted-by":"crossref","DOI":"10.1186\/s13044-020-00086-7","article-title":"Teprotumumab: a disease modifying treatment for graves\u2019 orbitopathy","volume":"13","author":"Ting","year":"2020","journal-title":"Thyroid Res"},{"key":"2026070711000229800_bib5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/IOP.0000000000001995","article-title":"Teprotumumab and hearing loss: case series and proposal for audiologic monitoring","volume":"38","author":"Belinsky","year":"2022","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"2026070711000229800_bib6","doi-asserted-by":"crossref","first-page":"A839","DOI":"10.1210\/jendso\/bvab048.1713","article-title":"Hearing loss and teprotumumab","volume":"5","author":"Kossler","year":"2021","journal-title":"J Endocr Soc"},{"key":"2026070711000229800_bib7","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ophtha.2023.10.018","article-title":"Teprotumumab-related adverse events in thyroid eye disease","volume":"131","author":"Shah","year":"2024","journal-title":"Ophthalmology"},{"key":"2026070711000229800_bib8","article-title":"A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patients","volume":"55","author":"Hiromatsu","year":"2025","journal-title":"Lancet Reg Health West Pac"},{"key":"2026070711000229800_bib9","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.eprac.2025.01.012","article-title":"Efficacy and safety of teprotumumab in thyroid eye disease: a systematic review and meta-analysis","volume":"31","author":"Huang","year":"2025","journal-title":"Endocr Pract"},{"key":"2026070711000229800_bib10","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/s41433-024-03531-1","article-title":"Risk of audiologic side effects with teprotumumab treatment for thyroid eye disease: propensity matched analysis","volume":"39","author":"Markle","year":"2025","journal-title":"Eye"},{"key":"2026070711000229800_bib11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1210\/clinem\/dgad637","article-title":"Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity","volume":"109","author":"Douglas","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070711000229800_bib12","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S2213-8587(21)00056-5","article-title":"Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials","volume":"9","author":"Kahaly","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026070711000229800_bib13","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N Engl J Med"},{"key":"2026070711000229800_bib14","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med"},{"key":"2026070711000229800_bib15","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/IOP.0000000000002668","article-title":"Teprotumumab-related hearing loss: a large-scale analysis and review of voluntarily reported patient complaints to the Food and Drug Administration (FDA)","volume":"40","author":"McGwin","year":"2024","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"2026070711000229800_bib16","article-title":"Adverse event reporting of the IGF-1R monoclonal antibody teprotumumab: a real-world study based on the US Food and Drug Administration adverse event reporting system","volume":"15","author":"Zhao","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026070711000229800_bib17","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1210\/clinem\/dgad213","article-title":"The adverse effects profile of teprotumumab","volume":"108","author":"Stan","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070711000229800_bib18","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/ohn.174","article-title":"Prospective assessment of otologic adverse events due to teprotumumab: preliminary results","volume":"168","author":"Kay-Rivest","year":"2023","journal-title":"Otolaryngol Head Neck Surg"},{"key":"2026070711000229800_bib19","first-page":"24","article-title":"Teprotumumab-associated hearing-related adverse events","volume":"12","author":"Key","year":"2024","journal-title":"Southwest Respir Crit Care Chron"},{"key":"2026070711000229800_bib20","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/MAO.0000000000004418","article-title":"Otologic symptoms following teprotumumab administration in patients with thyroid eye disease","volume":"46","author":"Epperson","year":"2025","journal-title":"Otol Neurotol"},{"key":"2026070711000229800_bib21","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ophtha.2023.08.001","article-title":"Frequency and patterns of hearing dysfunction in patients treated with teprotumumab","volume":"131","author":"Keen","year":"2024","journal-title":"Ophthalmology"},{"key":"2026070711000229800_bib22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/IOP.0000000000002078","article-title":"Rifle blast exacerbating hearing loss in a patient treated with teprotumumab for thyroid eye disease","volume":"38","author":"Reed","year":"2022","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"2026070711000229800_bib23","doi-asserted-by":"crossref","first-page":"e248335","DOI":"10.1136\/bcr-2021-248335","article-title":"Teprotumumab-associated chronic hearing loss screening and proposed treatments","volume":"15","author":"Chow","year":"2022","journal-title":"BMJ Case Rep"},{"key":"2026070711000229800_bib24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/IOP.0000000000002355","article-title":"Reduction of teprotumumab-Induced hearing loss with comparable efficacy using half-dose therapy","volume":"39","author":"Phansalkar","year":"2023","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"2026070711000229800_bib25","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1177\/00034894211042740","article-title":"Ototoxicity and teprotumumab","volume":"131","author":"Highland","year":"2021","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"2026070711000229800_bib26","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1210\/clinem\/dgae560","article-title":"Assessment of hearing dysfunction in patients with graves\u2019 disease and thyroid eye disease without or with teprotumumab","volume":"110","author":"Smith","year":"2025","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Endocrine Connections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/14\/7\/EC-25-0293.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ec.bioscientifica.com\/downloadpdf\/journals\/ec\/14\/7\/EC-25-0293.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article-pdf\/doi\/10.1530\/EC-25-0293\/9676\/ec-25-0293.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article-pdf\/doi\/10.1530\/EC-25-0293\/9676\/ec-25-0293.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T15:30:12Z","timestamp":1783438212000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article\/14\/7\/e250293\/1419\/Teprotumumab-and-sensorineural-hearing-loss-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1530\/ec-25-0293","relation":{},"ISSN":["2049-3614"],"issn-type":[{"value":"2049-3614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"article-number":"e250293"}}